首頁 > 市場調查報告書 > 醫療設備

整形外科

市場調查報告書

商品編碼

1410143

2023年至2028年Kifoplasty市場預測

Kyphoplasty Market - Forecasts from 2023 to 2028

出版日期: 2023年12月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021 年 Kifoplasty 市值為 799,574,000 美元，預計到 2028 年將以 5.48% 的複合年成長率成長至 1,161,548,000 美元。

Kifoplasty 是一種用於緩解脊椎壓迫性骨折引起的疼痛的醫療程序。當全部或部分脊椎塌陷時，就會發生這些骨折，導致不適和脊椎穩定性下降。透過接受 Kifoplasty，患者可以緩解疼痛並改善脊椎功能。 Kifoplasty 用於恢復脊椎排列和治療椎骨骨折。 Kifoplasty 的最終用戶包括醫院、診所和門診手術中心。

醫療保健產業的成長推動了 Kifoplasty 市場的成長

Kifoplasty 是一種安全有效的手術，用於治療骨質疏鬆症或外傷等疾病引起的疼痛性椎體壓迫性骨折。 Kifoplasty 提供了一種微創解決方案來穩定骨折的脊椎骨、恢復脊椎骨高度並緩解疼痛。透過政府措施擴大醫療保險和改善醫療服務的可近性正在促進整個醫療保健產業的成長和發展。

骨質疏鬆症盛行率的增加推動了 Kifoplasty 市場的擴張

Kifoplasty 用於治療與骨質疏鬆症相關的椎體壓迫性骨折。椎骨成形術是一種微創手術，涉及將球囊插入骨折的脊椎骨中並使其膨脹以形成空腔，然後注入骨水泥以穩定骨折並恢復脊椎骨的高度。骨質疏鬆症的增加主要是由於老化、久坐的生活方式以及鈣和維生素D攝取不足等因素造成的。根據自然醫學圖書館的數據，預計EU27+2地區每年骨質疏鬆性骨折的數量預計將從2019年的428萬起大幅增加至106萬起，到2034年總合達到505萬起。

微創推動 Kifoplasty 市場成長

Kifoplasty 是治療椎體骨折的傳統手術方法的微創替代方案。這種治療方法有幾個優點，包括住院時間更短、恢復時間更快和術後併發症更少，使其成為對患者和醫療保健提供者都有吸引力的選擇。由於整個過程通常需要不到一小時，Kifoplasty 是一種有吸引力的解決方案，可以有效解決脊椎相關問題、改善患者治療效果並減輕醫療機構的負擔。它是微創的，對於那些尋求破壞性較小且有效的治療方法來治療痛苦的椎骨骨折和脊椎後凸的人來說是首選。

預計北美將主導 Kifoplasty 市場

預計北美在 Kifoplasty 市場中佔據重要佔有率的主要原因是創傷性脊椎損傷發生率的上升以及政府的投資和舉措。根據 2021 年國家脊髓損傷統計中心的數據，美國每年每百萬人中約有 54 例創傷性脊髓損傷 (SCI)，導致每年約 18,000 例新增 SCI。這些數字突顯了創傷性脊髓損傷對人群的重大影響，並強調了對 Kifoplasty 等有效治療方法的需求。

與 Kifoplasty 相關的風險限制了 Kifoplasty 市場的成長。

與此手術相關的風險，例如感染、出血、背痛加劇以及神經損傷可能導致的麻木和虛弱，對整體市場成長構成了挑戰。此外，對引導 X光中使用的化學物質的潛在過敏反應以及水泥從預定位置意外洩漏的風險的擔憂也值得注意。這些風險阻止了一些患者選擇 Kifoplasty，儘管它在治療椎骨骨折和脊椎後凸方面已被證明有效，從而影響了市場成長。

Kyphoplasty is a medical procedure employed to alleviate pain caused by compression fractures in the spine. These fractures occur when all or a portion of a spine bone collapses, leading to discomfort and reduced spinal stability. By undergoing kyphoplasty, patients can experience relief from pain and improved spinal function. Kyphoplasty finds applications in the restoration of vertebral alignment and treatment of spinal fractures. The end users of kyphoplasty include hospitals & clinics as well as ambulatory surgical centers.

The rise in the healthcare sector bolsters the kyphoplasty market growth.

Kyphoplasty is a safe and effective procedure to treat painful vertebral compression fractures caused by conditions like osteoporosis and traumatic injuries. These fractures often result in severe pain and reduced mobility, and kyphoplasty offers a minimally invasive solution to stabilize the fractured vertebrae, restore vertebral height, and alleviate pain. The expansion of healthcare coverage and improved access to medical services driven by government initiatives contribute to the overall growth and development of the healthcare industry. For instance, in March 2022, Spine BioPharma secured a significant $14 million series B round of funding, earmarked to bolster its injectable treatment for degenerative disc disease.

Increasing prevalence of osteoporosis drives the kyphoplasty market expansion.

Kyphoplasty is used as a treatment for osteoporosis-related vertebral compression fractures, which occur due to weakened bones in individuals with osteoporosis. In kyphoplasty, a minimally invasive procedure, a balloon is inserted into the fractured vertebra and inflated to create a cavity, followed by the injection of bone cement to stabilize the fracture and restore vertebral height. Osteoporosis is increasing primarily due to factors such as an aging population, sedentary lifestyles, and inadequate calcium and vitamin D intake. According to the Natural Library of Medicine, the projected annual number of osteoporotic fractures in the EU27+2 region is anticipated to rise significantly by 1.06 million, reaching a total of 5.05 million cases in 2034, compared to 4.28 million cases in 2019.

Minimally invasive nature drives kyphoplasty market growth.

Kyphoplasty stands out as a less invasive alternative to conventional surgical methods for treating vertebral fractures. This procedure offers several advantages, including shorter hospital stays, quicker recovery times, and fewer post-operative complications, making it a compelling choice for patients and healthcare providers alike. With the entire process typically taking less than an hour, kyphoplasty presents an appealing solution for effectively addressing spine-related issues, improving patient outcomes, and reducing the burden on healthcare facilities. Its minimally invasive nature makes it a favorable option for those seeking a less disruptive and more efficient treatment approach for painful vertebral fractures and kyphosis.

North America is expected to dominate the kyphoplasty market.

North America is projected to hold a significant share of the kyphoplasty market primarily due to the escalating incidence of traumatic spinal injuries coupled with government investments and initiatives. For instance, in January 2022, under the leadership of UBC researchers, a groundbreaking project with funding of $24 million had been initiated to advance the treatment of spinal cord injuries. Also, according to the National Spinal Cord Injury Statistical Center in 2021, the United States witnessed an annual incidence of approximately 54 cases of traumatic spinal cord injury (SCI) per one million people, resulting in approximately 18,000 new SCI cases each year. This figure highlights the significant impact of traumatic spinal cord injuries on the population, emphasizing the need for effective treatments like kyphoplasty.

Risks involved in kyphoplasty restrain the kyphoplasty market growth.

The risks associated with the procedure such as infection, bleeding, increased back pain, and the possibility of numbness, or weakness due to nerve damage are posing a challenge to the overall market growth. Moreover, there are notable concerns regarding potential allergic reactions to chemicals utilized with X-rays for guidance and the risk of unintended cement leakage from its intended position. These risks may deter some patients from opting for kyphoplasty, impacting market growth despite its proven effectiveness in treating vertebral fractures and kyphosis.

Key Developments

August 2021: IZI Medical launched Vertefix HV Cement, providing physicians with an advanced solution to monitor and regulate the flow of cement during vertebroplasty and kyphoplasty procedures. This innovative product incorporates variable-sized barium particles with high viscosity, enabling precise tracking and control of cement distribution. As a result, Vertefix HV Cement significantly enhances procedural outcomes and ensures greater safety for patients, making it a valuable addition to the medical community's arsenal in treating related conditions effectively and with improved precision.
May 2020: Medtronic plc introduced the Kyphon Assist Directional Cannula in the United States, complementing its balloon kyphoplasty (BKP) products to address vertebral compression fractures arising from osteoporosis, cancer, or benign lesions. This novel device empowers physicians with enhanced control during bone tamp inflation and height restoration compared to conventional balloon kyphoplasty cannulas. The Kyphon Assist Directional Cannula represents a significant advancement in the treatment of vertebral fractures, enabling more precise and effective procedures for those suffering from these conditions.

Company Products

AVAflex Balloon System: Stryker's AVAflex balloon system offers a simplified and effective approach to treating vertebral compression fractures (VCFs) while achieving bipedicular results with a unipedicular approach. With its multiple balloon sizes and needle gauge options, AVAflex is designed to cater to various physician preferences and patient requirements. The system's curved coaxial needle allows for precise cement placement, ensuring an optimal fill within the vertebral body. With these advanced features, AVAflex empowers healthcare professionals to streamline VCF treatments, providing targeted and efficient solutions for improved patient outcomes.
KYPHON BALLOON KYPHOPLASTY PLATFORM: Medtronic's Kyphon is a groundbreaking innovation, offering several advantages over previous technologies. With a maximum rated inflation pressure of 700 psi, the balloons provide higher pressure capabilities compared to the previous 400 psi balloons. The cement resistance technique enables physicians to deliver cement through one cannula while maintaining fracture reduction by keeping the contralateral balloon inflated. Additionally, the Kyphon cement delivery system allows for cement delivery from up to 48 inches away from the radiation source during a kyphoplasty procedure.

Segmentation

By Product

Balloon Catheters
Bone Access Devices
Cement Application Products
Bone Cement
Cement Mixing Systems
Instruments

By Application

Vertebral Alignment Restoration
Spinal Fractures
Kyphosis

By End-Use

Hospitals & Clinics
Ambulatory Surgical Centers

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. KYPHOPLASTY MARKET, BY PRODUCT

5.1. Introduction
5.2. Balloon Catheters
5.3. Bone Access Devices
5.4. Cement Application Products
5.5. Bone Cement
5.6. Cement Mixing Systems
5.7. Instruments

6. KYPHOPLASTY MARKET, BY APPLICATION

6.1. Introduction
6.2. Vertebral Alignment Restoration
6.3. Spinal Fractures
6.4. Kyphosis

7. KYPHOPLASTY MARKET, BY END-USE

7.1. Introduction
7.2. Hospitals & Clinics
7.3. Ambulatory Surgical Centers

8. KYPHOPLASTY MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others